Anti-Inflammatory Effects of Angiotensin Receptor Blockers in the Brain and the Periphery
- 4 March 2009
- journal article
- review article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 29 (6-7) , 781-792
- https://doi.org/10.1007/s10571-009-9368-4
Abstract
In addition to regulating blood pressure, Angiotensin II (Ang II) exerts powerful pro-inflammatory effects in hypertension through stimulation of its AT1 receptors, most clearly demonstrated in peripheral arteries and in the cerebral vasculature. Administration of Ang II receptor blockers (ARBs) decreases hypertension-related vascular inflammation in peripheral organs. In rodent models of genetic hypertension, ARBs reverse the inflammation in the cerebral microcirculation. We hypothesized that ARBs could be effective in inflammatory conditions beyond hypertension. Our more recent studies, summarized here, indicate that this is indeed the case. We used the model of systemic administration of the bacterial endotoxin lipopolysaccharide (LPS). LPS produces a robust initial inflammatory reaction, the innate immune response, in peripheral organs and in the brain. Pretreatment with the ARB candesartan significantly diminishes the response to LPS, including reduction of pro-inflammatory cytokine release to the general circulation and decreased production and release of the pro-inflammatory adrenal hormone aldosterone. In addition, the ARB very significantly decreased the LPS-induced gene expression of pro-inflammatory cytokines and microglia activation in the brain. Our results demonstrate that AT1 receptor activity is essential for the unrestricted development of full-scale innate immune response in the periphery and in the brain. ARBs, due to their immune response-limiting properties, may be considered as therapeutically useful in a number of inflammatory diseases of the peripheral organs and the brain.Keywords
This publication has 78 references indexed in Scilit:
- Predictors of Cognitive Decline in Older Individuals With DiabetesDiabetes Care, 2008
- The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discoveryFundamental & Clinical Pharmacology, 2008
- Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1β and anti-inflammatory IL-10 cytokinesBrain, Behavior, and Immunity, 2008
- Immune-To-Brain Signaling: How Important are the Blood–Brain Barrier-independent Pathways?Molecular Neurobiology, 2008
- Angiotensin II AT1 Receptor Blockade Decreases Lipopolysaccharide-Induced Inflammation in the Rat Adrenal GlandEndocrinology, 2008
- Angiotensin II AT1receptor blockade selectively enhances brain AT2receptor expression, and abolishes the cold-restraint stress-induced increase in tyrosine hydroxylase mRNA in the locus coeruleus of spontaneously hypertensive ratsStress, 2008
- Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stressBrain Research, 2007
- Systemic LPS causes chronic neuroinflammation and progressive neurodegenerationGlia, 2007
- Mechanisms of the Anti-Ischemic Effect of Angiotensin II AT1 Receptor Antagonists in the BrainCellular and Molecular Neurobiology, 2006
- Brain Angiotensin II: New Developments, Unanswered Questions and Therapeutic OpportunitiesCellular and Molecular Neurobiology, 2005